LeMaitre Vascular (NASDAQ:LMAT) will issue its quarterly earnings data after the market closes on Wednesday, July 24th. Analysts expect the company to announce earnings of $0.21 per share for the quarter. LeMaitre Vascular has set its Q2 guidance at $0.20-22 EPS and its FY19 guidance at $0.82-0.86 EPS.Parties that wish to listen to the company’s conference call can do so using this link.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, May 1st. The medical instruments supplier reported $0.17 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.02). LeMaitre Vascular had a net margin of 20.92% and a return on equity of 16.76%. The business had revenue of $28.48 million during the quarter, compared to analyst estimates of $27.94 million. During the same quarter last year, the business posted $0.19 earnings per share. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. On average, analysts expect LeMaitre Vascular to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Shares of NASDAQ:LMAT opened at $31.53 on Tuesday. The firm has a fifty day simple moving average of $27.79. The firm has a market capitalization of $598.40 million, a price-to-earnings ratio of 37.54, a PEG ratio of 3.05 and a beta of 1.15. LeMaitre Vascular has a twelve month low of $21.79 and a twelve month high of $38.99.

Several research firms recently issued reports on LMAT. Barrington Research set a $64.00 price target on SurModics and gave the company a “buy” rating in a report on Thursday, May 2nd. ValuEngine upgraded Zumiez from a “sell” rating to a “hold” rating in a report on Monday. BidaskClub cut Westport Fuel Systems from a “buy” rating to a “hold” rating in a report on Friday. Finally, Zacks Investment Research cut GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a report on Tuesday, May 7th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $31.00.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

See Also: Quiet Period Expirations

Earnings History for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.